BioCentury
ARTICLE | Product Development

Lilly, AbCellera antiviral COVID-19 mAb begins mobile Phase III prevention study

Plus non-human primate and hamster data from Regeneron COVID-19 mAb cocktail

August 4, 2020 1:39 AM UTC

Phase III trials of the two most advanced antiviral COVID-19 mAbs, from Lilly and partner AbCellera and from Regeneron, both aim to prevent infection in exposed individuals but address different study populations.

Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. announced Monday the start of the Phase III BLAZE-2 trial of Ly-CoV555 to prevent COVID-19, the same day Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) unveiled data in rhesus macaques and hamsters for its REGN-COV2. ...